Bacterial meningitis early management: Difference between revisions
Jump to navigation
Jump to search
/* EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.{{cite journal| author=Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, A... |
/* EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.{{cite journal| author=Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, A... |
||
Line 59: | Line 59: | ||
* Listerial meningitis: [[Ampicillin]] or [[Amoxicillin]] 2 g 4 hourly ± [[Gentamicin]] 1 to 2 mg 8 hourly for the first 7 to 10 days [IVC]. | * Listerial meningitis: [[Ampicillin]] or [[Amoxicillin]] 2 g 4 hourly ± [[Gentamicin]] 1 to 2 mg 8 hourly for the first 7 to 10 days [IVC]. | ||
* Alternative therapy: [[Trimethoprim]]–[[Sulfamethoxazole]] 10 to 20 mg/kg 6 to 12 hourly or Meropenem [IV] | * Alternative therapy: [[Trimethoprim]]–[[Sulfamethoxazole]] 10 to 20 mg/kg 6 to 12 hourly or Meropenem [IV] | ||
Staphylococcal species: Flucloxacillin 2 g 4 hourly [IV] or Vancomycin if penicillin allergy is suspected [IV]. Rifampicin should also be considered in addition to either agent, and Linezolid for methicillin-resistant staphylococcal meningitis [IVC]. | ====Staphylococcal species==== | ||
Gram-negative Enterobacteriaceae: Ceftriaxone or Cefotaxime or Meropenem | * Staphylococcal species: [[Flucloxacillin]] 2 g 4 hourly [IV] or [[Vancomycin]] if penicillin allergy is suspected [IV]. | ||
Pseudomonal meningitis: Meropenem ± Gentamicin | * Rifampicin should also be considered in addition to either agent, and Linezolid for methicillin-resistant staphylococcal meningitis [IVC]. | ||
====Gram-negative Enterobacteriaceae==== | |||
* Gram-negative Enterobacteriaceae: Ceftriaxone or Cefotaxime or Meropenem | |||
====Pseudomonal meningitis==== | |||
* Pseudomonal meningitis: Meropenem ± Gentamicin | |||
}} | }} | ||
Revision as of 16:10, 30 September 2012
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Early Management of Acute Bacterial Meningitis (ABM)
|
” |
EFNS guideline on the Empirical Antibiotic Therapy in Suspected ABM of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Specific Antibiotic Treatment
Empirical Antibiotic Therapy in Suspected ABM
|
” |
EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Pathogen Specific Antibiotic Therapy in Suspected ABMPneumococcal meningitis
Meningococcal meningitis
Haemophilus influenzae type B (Hib)
Listerial meningitis
Staphylococcal species
Gram-negative Enterobacteriaceae
Pseudomonal meningitis
|
” |
References
- ↑ 1.0 1.1 1.2 Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, Andrew Seaton R, Portegies P; et al. (2008). "EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults". Eur J Neurol. 15 (7): 649–59. doi:10.1111/j.1468-1331.2008.02193.x. PMID 18582342.